Strategies for herpes zoster vaccination of immunocompromised patients.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 18419403.
- Also identified by DOI 10.1086/522129 and PMC identifier 2679676.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
A vaccine to prevent herpes zoster (HZ) in adults > or =60 years of age with healthy immune systems was recently approved by the US Food and Drug Administration. This vaccine is contraindicated in persons with certain immunodeficiency states or who are receiving immunosuppressive therapy. On the basis of studies of the varicella vaccine in healthy and immunosuppressed children and studies of HZ vaccine in healthy adults before its licensure, a series of strategies are proposed for evaluating the live HZ vaccine in immunosuppressed persons. In addition, the use of other vaccines, including heat-inactivated or replication-defective varicella-zoster virus to prevent HZ in immunocompromised persons, is also discussed.
Medical subject headings
- Herpes Zoster
- Herpes Zoster Vaccine
- Herpesvirus 3, Human
- Immunocompromised Host
- Vaccination